Figures computed from official regulatory filings — .
Analysttarget 29.5 USD (+177%) · consensus 5/5 · 7 buy · 0 hold · 0 sell
Ownershipinsiders 0.94% · institutions 41.33% · short 7.6% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Adlai Nortye Group Ltd. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
7 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Ji Ping |
| Sell |
| $80.2K |
| SEC |
| Ji Ping | Sell | $79.8K | SEC |
| Ji Ping | Sell | $83.2K | SEC |
| Ye Xiaofeng | Sell | $80.8K | SEC |
| Ye Xiaofeng | Sell | $83.9K | SEC |
| Ji Ping | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LU YANG | Sell | $131.8 | SEC |